Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

被引：3
|
作者：
Phillips, Tycel [1 ]
Lugtenburg, Pieternella [2 ]
Kalsekar, Anupama [3 ]
Mutebi, Alex [3 ]
Wang, Anthony [4 ]
Blaedel, Julie [3 ]
Kosa, Katherine [5 ]
Martin, Susan [5 ]
Sacchi, Mariana [3 ]
Thieblemont, Catherine [6 ,7 ]
机构：
[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA
[2] Erasmus MC, Dept Hematol, HOVON Lymphoma Working Grp, Canc Inst,Univ Med Ctr, Rotterdam, Netherlands
[3] Genmab, Princeton, NJ USA
[4] AbbVie Inc, N Chicago, IL USA
[5] RTI Hlth Solut, Ann Arbor, MI USA
[6] Hop St Louis, AP HP, Paris, France
[7] Diderot Univ, Sorbonne Paris Cite, Paris, France
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159544
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8022 / 8023
页数：2
相关论文
共 50 条
  • [41] Practice Efficiency Associated with Epcoritamab for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma from an Institutional Perspective
    Lei, Matthew M.
    Li, Qianyi
    O'Day, Ken
    Meyer, Kellie
    Wang, Anthony
    Jun, Monika
    BLOOD, 2023, 142
  • [42] Phase 1b Trial of Subcutaneous Epcoritamab in Pediatric Patients with Relapsed or Refractory (R/R) Aggressive Mature B-Cell Neoplasms (EPCORE Peds-1)
    Cairo, Mitchell S.
    Rocco, Mark A.
    Bernard, John
    Siddani, Satya R.
    Parikh, Apurvasena
    Elliott, Brian
    Burkhardt, Birgit
    BLOOD, 2022, 140 : 3827 - 3828
  • [43] Epcoritamab SC plus GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2
    Brody, Joshua
    Joergensen, Judit Meszaros
    Belada, David
    Costello, Regis T.
    Trneny, Marek
    Vitolo, Umberto
    Lewis, David
    Karimi, Yasmin H.
    Sureda Balari, Anna Maria
    Andre, Marc
    Wahlin, Bjorn E.
    Lugtenburg, Pieternella
    Galderisi, Faith
    Abbas, Aqeel
    Song, Yaou
    Risum, Malene
    Cordoba, Raul
    BLOOD, 2023, 142
  • [44] Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma
    Davis, James A.
    Granger, Katelynn
    Sakowski, Alex
    Goodwin, Sara
    Herbst, Amanda
    Smith, Deidra
    Hendrickson, Lindsey
    Nachar, Victoria R.
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (12) : 915 - 918
  • [45] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    Hutchings, Martin
    Mous, Rogier
    Clausen, Michael Roost
    Johnson, Peter
    Linton, Kim M.
    Chamuleau, Martine E. D.
    Lewis, David John
    Balari, Anna Sureda
    Cunningham, David
    Oliveri, Roberto S.
    Elliott, Brian
    DeMarco, Dena
    Azaryan, Ada
    Chiu, Christopher
    Li, Tommy
    Chen, Kuo-mei
    Ahmadi, Tahamtan
    Lugtenburg, Pieternella J.
    LANCET, 2021, 398 (10306): : 1157 - 1169
  • [46] Subcutaneous Epcoritamab plus R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results
    Abrisqueta, Pau
    Cordoba, Raul
    Falchi, Lorenzo
    de Vos, Sven
    Nijland, Marcel
    Offner, Fritz
    Wu, Jun
    Bykhovski, Irina
    Wang, Liwei
    Rana, Ali
    Phillips, Tycel
    BLOOD, 2022, 140 : 1068 - 1069
  • [47] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Ren, Liangliang
    Li, Ling
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Yan, Jiaqin
    Kong, Fei
    Zhang, Mingzhi
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 42 - 50
  • [48] A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients
    Jiang, Shiyu
    Qin, Yan
    Liu, Peng
    Yang, Jianliang
    Yang, Sheng
    He, Xiaohui
    Zhou, Shengyu
    Gui, Lin
    Zhang, Changgong
    Zhou, Liqiang
    Sun, Yan
    Shi, Yuankai
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) : E11 - E16
  • [49] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Liangliang Ren
    Ling Li
    Lei Zhang
    Xin Li
    Xiaorui Fu
    Xinhua Wang
    Jingjing Wu
    Zhenchang Sun
    Xiaoyan Feng
    Yu Chang
    Zhiyuan Zhou
    Feifei Nan
    Jiaqin Yan
    Fei Kong
    Mingzhi Zhang
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 42 - 50
  • [50] DeVIC chemotherapy is effective for patients with refractory or relapsed diffuse large B-cell lymphoma
    Okada, Kazuya
    Sakai, Kazuya
    Muranushi, Hiroyuki
    Okamoto, Yusuke
    Sugiura, Hiroyuki
    Sato, Aki
    Sato, Takayuki
    Maeda, Takeshi
    Onishi, Tatsuhito
    Ueda, Yasunori
    ANNALS OF ONCOLOGY, 2015, 26 : 108 - 108
12345